Research programme: inflammatory bowel disorders therapy - Aphoenix

Drug Profile

Research programme: inflammatory bowel disorders therapy - Aphoenix

Alternative Names: AFX 003 series; AFX-300 series for inflammatory bowel disease; Inflammatory bowel disorders therapy research programme - Aphoenix

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aphoenix
  • Class Small molecules
  • Mechanism of Action Chloride channel antagonists; Cytokine inhibitors; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in Japan
  • 01 Jul 2005 Aphoenix has completed preclinical trials in Inflammatory bowel disorders in Japan
  • 01 Jul 2004 AFX 003 series is available for partnering (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top